Antibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations
- Western blot [2]
- Immunohistochemistry [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- NBP1-76639 - Provider product page
- Provider
- Novus Biologicals
- Proper citation
- Novus Cat#NBP1-76639, RRID:AB_11023149
- Product name
- Rabbit Polyclonal PUMA Antibody
- Antibody type
- Polyclonal
- Description
- Peptide affinity purified.
- Reactivity
- Human, Rat
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 0.1 mg
- Concentration
- 1 mg/ml
- Storage
- Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Submitted references Temporal and differential regulation of KAISO-controlled transcription by phosphorylated and acetylated p53 highlights a crucial regulatory role of apoptosis.
p73 engages A2B receptor signalling to prime cancer cells to chemotherapy-induced death.
Flavopiridol synergizes TRAIL cytotoxicity by downregulation of FLIPL.
Targeted deletion of Puma attenuates cardiomyocyte death and improves cardiac function during ischemia-reperfusion.
PUMA expression is significantly reduced in human cutaneous melanomas.
Choi SH, Koh DI, Cho SY, Kim MK, Kim KS, Hur MW
The Journal of biological chemistry 2019 Aug 30;294(35):12957-12974
The Journal of biological chemistry 2019 Aug 30;294(35):12957-12974
p73 engages A2B receptor signalling to prime cancer cells to chemotherapy-induced death.
Long JS, Schoonen PM, Graczyk D, O'Prey J, Ryan KM
Oncogene 2015 Oct 1;34(40):5152-62
Oncogene 2015 Oct 1;34(40):5152-62
Flavopiridol synergizes TRAIL cytotoxicity by downregulation of FLIPL.
Fandy TE, Ross DD, Gore SD, Srivastava RK
Cancer chemotherapy and pharmacology 2007 Aug;60(3):313-9
Cancer chemotherapy and pharmacology 2007 Aug;60(3):313-9
Targeted deletion of Puma attenuates cardiomyocyte death and improves cardiac function during ischemia-reperfusion.
Toth A, Jeffers JR, Nickson P, Min JY, Morgan JP, Zambetti GP, Erhardt P
American journal of physiology. Heart and circulatory physiology 2006 Jul;291(1):H52-60
American journal of physiology. Heart and circulatory physiology 2006 Jul;291(1):H52-60
PUMA expression is significantly reduced in human cutaneous melanomas.
Karst AM, Dai DL, Martinka M, Li G
Oncogene 2005 Feb 3;24(6):1111-6
Oncogene 2005 Feb 3;24(6):1111-6
No comments: Submit comment
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Western Blot: PUMA Antibody [NBP1-76639] - K562 cell lysate with PUMA antibody at 2 ug/ml.
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Western Blot: PUMA Antibody [NBP1-76639] - Independent Antibody Validation (IAV) via Protein Expression Profile Loading: 20 ug of lysates per lane. Antibodies: NBP1-76654 (3 ug/mL), NBP1-76639 (2 ug/mL), beta-actin (1 ug/mL) and GAPDH (0.02 ug/mL), 1 h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate.
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Immunohistochemistry-Paraffin: PUMA Antibody [NBP1-76639] - Human breast carcinoma with PUMA antibody at 10 ug/mL. Immunohistochemistry of PUMA in human breast carcinoma with PUMA antibody at 10 ug/mL.
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Immunohistochemistry: PUMA Antibody [NBP1-76639] - Analysis of PUMA in human breast tissue with PUMA antibody at 2.5 ug/ml.